ADMA
Price
$18.16
Change
-$0.24 (-1.30%)
Updated
Jun 27 closing price
Capitalization
4.33B
38 days until earnings call
CAI
Price
$26.81
Change
+$0.06 (+0.22%)
Updated
Jun 27 closing price
Capitalization
7.45B
Interact to see
Advertisement

ADMA vs CAI

Header iconADMA vs CAI Comparison
Open Charts ADMA vs CAIBanner chart's image
ADMA Biologics
Price$18.16
Change-$0.24 (-1.30%)
Volume$4.94M
Capitalization4.33B
Caris Life Sciences
Price$26.81
Change+$0.06 (+0.22%)
Volume$536.02K
Capitalization7.45B
ADMA vs CAI Comparison Chart in %
Loading...
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADMA vs. CAI commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Buy and CAI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ADMA: $18.16 vs. CAI: $26.81)
Brand notoriety: ADMA and CAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 140% vs. CAI: 82%
Market capitalization -- ADMA: $4.33B vs. CAI: $7.45B
ADMA [@Biotechnology] is valued at $4.33B. CAI’s [@Biotechnology] market capitalization is $7.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileCAI’s FA Score has 1 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • CAI’s FA Score: 1 green, 4 red.
According to our system of comparison, ADMA is a better buy in the long-term than CAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 3 TA indicator(s) are bullish while CAI’s TA Score has 2 bullish TA indicator(s).

  • ADMA’s TA Score: 3 bullish, 4 bearish.
  • CAI’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, CAI is a better buy in the short-term than ADMA.

Price Growth

ADMA (@Biotechnology) experienced а +2.37% price change this week, while CAI (@Biotechnology) price change was -4.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ADMA is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CAI($7.45B) has a higher market cap than ADMA($4.33B). ADMA YTD gains are higher at: 5.889 vs. CAI (-52.125). ADMA has higher annual earnings (EBITDA): 161M vs. CAI (-181.67M). ADMA has more cash in the bank: 71.6M vs. CAI (33.4M). ADMA has less debt than CAI: ADMA (82M) vs CAI (420M). ADMA (459M) and CAI (452M) have equivalent revenues.
ADMACAIADMA / CAI
Capitalization4.33B7.45B58%
EBITDA161M-181.67M-89%
Gain YTD5.889-52.125-11%
P/E Ratio21.61N/A-
Revenue459M452M102%
Total Cash71.6M33.4M214%
Total Debt82M420M20%
FUNDAMENTALS RATINGS
ADMA vs CAI: Fundamental Ratings
ADMA
CAI
OUTLOOK RATING
1..100
6196
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
1778
SMR RATING
1..100
1554
PRICE GROWTH RATING
1..100
5397
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAI's Valuation (2) in the Finance Or Rental Or Leasing industry is significantly better than the same rating for ADMA (75) in the Biotechnology industry. This means that CAI’s stock grew significantly faster than ADMA’s over the last 12 months.

ADMA's Profit vs Risk Rating (17) in the Biotechnology industry is somewhat better than the same rating for CAI (78) in the Finance Or Rental Or Leasing industry. This means that ADMA’s stock grew somewhat faster than CAI’s over the last 12 months.

ADMA's SMR Rating (15) in the Biotechnology industry is somewhat better than the same rating for CAI (54) in the Finance Or Rental Or Leasing industry. This means that ADMA’s stock grew somewhat faster than CAI’s over the last 12 months.

ADMA's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for CAI (97) in the Finance Or Rental Or Leasing industry. This means that ADMA’s stock grew somewhat faster than CAI’s over the last 12 months.

ADMA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CAI (100) in the Finance Or Rental Or Leasing industry. This means that ADMA’s stock grew similarly to CAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMACAI
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
63%
Momentum
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
40%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
45%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
54%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 10 days ago
75%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PQJA26.500.20
+0.75%
PGIM NASDAQ-100 BUFFER 12 ETF - JANUARY
PHT8.06-0.01
-0.12%
Pioneer High Income Fund
IQHI26.29-0.04
-0.15%
NYLI MacKay High Income ETF
SPIP25.98-0.05
-0.17%
SPDR® Portfolio TIPS ETF
ZTAX25.10-0.10
-0.40%
X-Square Municipal Income Tax Free ETF

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with IMTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then IMTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
-1.30%
IMTX - ADMA
42%
Loosely correlated
-2.86%
TARS - ADMA
42%
Loosely correlated
+0.05%
ACLX - ADMA
40%
Loosely correlated
+0.90%
RYTM - ADMA
39%
Loosely correlated
+2.09%
ROIV - ADMA
38%
Loosely correlated
-1.81%
More

CAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, CAI has been loosely correlated with BMEA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CAI jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAI
1D Price
Change %
CAI100%
+0.22%
BMEA - CAI
38%
Loosely correlated
-9.05%
LIXT - CAI
27%
Poorly correlated
-7.19%
VTGN - CAI
27%
Poorly correlated
-3.90%
CERO - CAI
22%
Poorly correlated
-14.66%
ADMA - CAI
7%
Poorly correlated
-1.30%
More